Developer docs
API playgroundTry for free, no card

Search company profiles

CARA

Full company profile

uuid0003vy3

Namestring
CARA
Legal namestring
CARA Technologies
Websiteurl
carasystems.co
Company typeenum
Private
Founded yearint
2023
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBrooklyn, United States
HQ citystring
Brooklyn
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI clinical decision support, neurovascular diagnostics, aneurysm risk prediction, medical imaging AI, healthcare SaaS
Industry3 codes
1Diagnostic & Triage Decision Support
CodeHLACAGAAPrimaryYes
2SaMD – Imaging & Signal Analysis (AI/ML)
CodeHLACANAGPrimaryNo
3Medical Imaging AI
CodeHDAAAEAHPrimaryNo
NAICS code2 codes
  • Software Publishers5132
  • Other Computer Related Services541519
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
AI Clinical Decision Support for Neurovascular Care
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Subscription Plans
TypeSubscription Recurring
Description

Flexible subscription plans for healthcare institutions of all sizes, offering recurring revenue with tiered access to AneuView™️ features and capabilities.

carasystems.co
2Pay-per-use
TypeUsage Based
Description

Flexible pay-per-use option allowing hospitals to pay only for the cases analyzed, offering consumption-based billing for institutions preferring variable cost structures.

carasystems.co
3One-time Implementation
TypeOne Time License
Description

One-time fixed implementation fee for initial deployment, customization, and training services.

carasystems.co
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Pricing details3 tiers
1Subscription plan for ongoing access
ModelSubscriptionBilling cadenceAnnual
Notes

Choose a subscription plan that suits your need - flexible options for different institution sizes

carasystems.co
2Pay-per-use for variable volume
ModelUsage-basedBilling cadencePay-as-you-go
Notes

Pay only for the cases analyzed - flexible consumption-based pricing

carasystems.co
3Implementation and onboarding
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

One-time fixed implementation fee including customized support and training

carasystems.co
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1AneuView™️
Description

AI-Copilot for neurospecialists providing clinical decision intelligence for precision neurovascular care, including risk scoring, interpretable rupture prediction, multimodal intelligence, workflow automation, longitudinal monitoring, proven cost savings, seamless EHR integration, and cloud-native SaaS delivery.

carasystems.co
Core offering1 text field

CARA sells AneuView™️, a cloud-native SaaS clinical decision intelligence platform that uses proprietary AI to fuse medical imaging, hemodynamic, and clinical data into interpretable brain aneurysm rupture risk predictions and neurovascular triage scores for neurospecialists at the point of care. The offering is delivered to hospitals through flexible subscription plans, pay-per-use case-based billing, and one-time implementation/onboarding fees, and includes Epic-ready EHR integration and longitudinal patient monitoring.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 50-70% reduction in manual imaging workload
+4 more records
Product overview1 text field

CARA offers a single unified AI-powered product called AneuView™️ — a clinical decision intelligence engine for precision neurovascular care. The platform serves as an AI-Copilot for Neurospecialists, combining multimodal intelligence (imaging + hemodynamics + clinical data) with workflow automation capabilities. Key features include AI-powered risk scoring, longitudinal monitoring of aneurysm changes over time, seamless EHR integration (Epic-ready), and cloud-native SaaS delivery. The system is designed for acute clinical settings, enabling evidence-based, timely interventions for aneurysm and stroke cases.

Product and service1 record
1AneuView™️
CategoryAI Clinical Decision Support for Neurovascular Care
Description

Cloud-native SaaS clinical decision intelligence platform that combines AI-powered risk scoring, multimodal data fusion (imaging + hemodynamics + clinical data), workflow automation, longitudinal aneurysm monitoring, and Epic-ready EHR integration to deliver interpretable brain aneurysm rupture risk predictions and neurovascular triage for neurospecialists at the point of care in academic medical centers and stroke hospitals.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Robust clinical collaboration with NYU Langone for validation studies and pilot programs. Dr. Albert S. Favate, Division Chief of Vascular Neurology, serves as clinical collaborator and provides testimonial on CARA's platform transforming risk evaluation and triage workflows.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical collaboration for validation studies and early pilot programs in neurovascular care, contributing to the development and clinical validation of CARA's AI-driven decision support system.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partnerships with leading academic medical centers and stroke hospitals. These collaborations drive validation studies and early pilot programs with top clinicians to validate and refine the AneuView™️ platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Viz.ai is a direct competitor offering AI-powered clinical decision support and workflow coordination for neurovascular conditions, particularly stroke and aneurysm triage. Both companies target similar academic medical centers and high-volume stroke centers with similar enterprise SaaS models.

TypeDirect peer
Description

RapidAI provides AI-driven neuroimaging analysis for stroke and aneurysm care, with FDA-cleared products serving similar hospital neurology and radiology workflows. Directly comparable in target customers (academic medical centers, stroke centers), use cases (cerebrovascular triage), and product category (clinical decision support AI).

TypeDirect peer
Description

Aidoc provides AI-powered workflow and decision support for medical imaging, including neurovascular findings such as aneurysm detection. Comparable as a hospital-deployed AI imaging platform with enterprise SaaS distribution to academic centers.

TypeDirect peer
Description

Brainomix develops AI-based imaging biomarkers for stroke and cerebrovascular disease assessment, deployed across hospital networks globally. Comparable as an AI medical imaging company targeting stroke centers with similar clinical decision support functionality.

TypeEmerging player
Description

Avicenna.AI develops AI tools for medical imaging workflow triage, with FDA-cleared products covering neurovascular and other acute findings. Comparable as a focused medical imaging AI company addressing hospital triage and workflow challenges.

TypeBroad incumbent
Description

Siemens Healthineers offers AI-Rad Companion, a broad radiology AI portfolio deployed across hospital systems, including capabilities relevant to neuroimaging workflows. Comparable as a broad incumbent with imaging AI capabilities that could expand into neurovascular triage at scale.

TypeBroad incumbent
Description

GE HealthCare's Edison AI platform provides imaging AI and clinical decision support integrated into hospital radiology and neurology workflows. Comparable as a broad incumbent whose imaging AI ecosystem overlaps with CARA's enterprise hospital go-to-market motion.

TypeRegional player
Description

Circle CVI provides AI-driven cardiac and vascular MR/CT imaging analysis, including cerebral aneurysm assessment tools. Comparable as an adjacent imaging AI vendor in cardiovascular/cerebrovascular analysis with similar hospital SaaS deployment.

TypeDirect peer
Description

icometrix develops AI-based imaging biomarkers for neurological conditions including stroke and other cerebrovascular disorders. Comparable as an AI neuro-imaging company with similar clinical evidence-driven approach and enterprise hospital distribution.

TypeEmerging player
Description

Nico.lab offers AI-based stroke imaging analysis tools (e.g., StrokeViewer) for emergency and neurovascular workflows. Comparable as a focused neurovascular AI company targeting similar clinical use cases in acute stroke triage.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CARA

AI Clinical Decision Support for Neurovascular Carecarasystems.co

CARA firmographics

Firmographics
Name
CARA
Legal name
CARA Technologies
Website
https://carasystems.co
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

CARA industry classification

Industry
Product category
AI Clinical Decision Support for Neurovascular Care
NAICS
Software Publishers (5132), Other Computer Related Services (541519)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro primary industry
Diagnostic & Triage Decision Support (HLACAGAA)
akta.pro secondary industries
SaMD – Imaging & Signal Analysis (AI/ML) (HLACANAG), Medical Imaging AI (HDAAAEAH)

Keywords

  • AI clinical decision support
  • Neurovascular diagnostics
  • Aneurysm risk prediction
  • Medical imaging AI
  • Healthcare SaaS

Where CARA is headquartered

Location

Headquarters

HQ city
Brooklyn
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CARA business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Subscription Plans: Flexible subscription plans for healthcare institutions of all sizes, offering recurring revenue with tiered access to AneuView™️ features and capabilities.
  2. Pay-per-use: Flexible pay-per-use option allowing hospitals to pay only for the cases analyzed, offering consumption-based billing for institutions preferring variable cost structures.
  3. One-time Implementation: One-time fixed implementation fee for initial deployment, customization, and training services.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualSubscription plan for ongoing access
Usage-basedPay-as-you-goPay-per-use for variable volume
One time/ perpetual licenseMulti-year contractImplementation and onboarding

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

CARA product offering

Product offering

Core offering

CARA sells AneuView™️, a cloud-native SaaS clinical decision intelligence platform that uses proprietary AI to fuse medical imaging, hemodynamic, and clinical data into interpretable brain aneurysm rupture risk predictions and neurovascular triage scores for neurospecialists at the point of care. The offering is delivered to hospitals through flexible subscription plans, pay-per-use case-based billing, and one-time implementation/onboarding fees, and includes Epic-ready EHR integration and longitudinal patient monitoring.

Product overview

CARA offers a single unified AI-powered product called AneuView™️ — a clinical decision intelligence engine for precision neurovascular care. The platform serves as an AI-Copilot for Neurospecialists, combining multimodal intelligence (imaging + hemodynamics + clinical data) with workflow automation capabilities. Key features include AI-powered risk scoring, longitudinal monitoring of aneurysm changes over time, seamless EHR integration (Epic-ready), and cloud-native SaaS delivery. The system is designed for acute clinical settings, enabling evidence-based, timely interventions for aneurysm and stroke cases.

Differentiator

Problem solved

Functional benefit

Brands

  • AneuView™️: AI-Copilot for neurospecialists providing clinical decision intelligence for precision neurovascular care, including risk scoring, interpretable rupture prediction, multimodal intelligence, workflow automation, longitudinal monitoring, proven cost savings, seamless EHR integration, and cloud-native SaaS delivery.

Products and services

  • AneuView™️ Cloud-native SaaS clinical decision intelligence platform that combines AI-powered risk scoring, multimodal data fusion (imaging + hemodynamics + clinical data), workflow automation, longitudinal aneurysm monitoring, and Epic-ready EHR integration to deliver interpretable brain aneurysm rupture risk predictions and neurovascular triage for neurospecialists at the point of care in academic medical centers and stroke hospitals.

Quantifiable outcome

  • 50-70% reduction in manual imaging workload
  • +4 more outcomes

Companies that use CARA

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

CARA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability6 records

Feature7 records

CARA partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • NYU Langone HealthcoreStrategic or Co-development PartnerRobust clinical collaboration with NYU Langone for validation studies and pilot programs. Dr. Albert S. Favate, Division Chief of Vascular Neurology, serves as clinical collaborator and provides testimonial on CARA's platform transforming risk evaluation and triage workflows.
  • Bellevue HospitalcoreStrategic or Co-development PartnerClinical collaboration for validation studies and early pilot programs in neurovascular care, contributing to the development and clinical validation of CARA's AI-driven decision support system.
  • Academic Medical Centers (Partners)coreStrategic or Co-development PartnerStrategic partnerships with leading academic medical centers and stroke hospitals. These collaborations drive validation studies and early pilot programs with top clinicians to validate and refine the AneuView™️ platform.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

CARA competitors and assessment

Company assessment

Direct peers

  • Viz.ai: Viz.ai is a direct competitor offering AI-powered clinical decision support and workflow coordination for neurovascular conditions, particularly stroke and aneurysm triage. Both companies target similar academic medical centers and high-volume stroke centers with similar enterprise SaaS models.
  • RapidAI: RapidAI provides AI-driven neuroimaging analysis for stroke and aneurysm care, with FDA-cleared products serving similar hospital neurology and radiology workflows. Directly comparable in target customers (academic medical centers, stroke centers), use cases (cerebrovascular triage), and product category (clinical decision support AI).
  • Aidoc: Aidoc provides AI-powered workflow and decision support for medical imaging, including neurovascular findings such as aneurysm detection. Comparable as a hospital-deployed AI imaging platform with enterprise SaaS distribution to academic centers.
  • Brainomix: Brainomix develops AI-based imaging biomarkers for stroke and cerebrovascular disease assessment, deployed across hospital networks globally. Comparable as an AI medical imaging company targeting stroke centers with similar clinical decision support functionality.
  • icometrix: icometrix develops AI-based imaging biomarkers for neurological conditions including stroke and other cerebrovascular disorders. Comparable as an AI neuro-imaging company with similar clinical evidence-driven approach and enterprise hospital distribution.

Emerging players

  • Avicenna.AI: Avicenna.AI develops AI tools for medical imaging workflow triage, with FDA-cleared products covering neurovascular and other acute findings. Comparable as a focused medical imaging AI company addressing hospital triage and workflow challenges.
  • Nico.lab: Nico.lab offers AI-based stroke imaging analysis tools (e.g., StrokeViewer) for emergency and neurovascular workflows. Comparable as a focused neurovascular AI company targeting similar clinical use cases in acute stroke triage.

Broad incumbents

  • Siemens Healthineers (AI-Rad Companion): Siemens Healthineers offers AI-Rad Companion, a broad radiology AI portfolio deployed across hospital systems, including capabilities relevant to neuroimaging workflows. Comparable as a broad incumbent with imaging AI capabilities that could expand into neurovascular triage at scale.
  • GE HealthCare (Edison AI): GE HealthCare's Edison AI platform provides imaging AI and clinical decision support integrated into hospital radiology and neurology workflows. Comparable as a broad incumbent whose imaging AI ecosystem overlaps with CARA's enterprise hospital go-to-market motion.

Regional players

  • Circle Cardiovascular Imaging: Circle CVI provides AI-driven cardiac and vascular MR/CT imaging analysis, including cerebral aneurysm assessment tools. Comparable as an adjacent imaging AI vendor in cardiovascular/cerebrovascular analysis with similar hospital SaaS deployment.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

CARA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CARA leadership team

Management profile

Number of profiles

Profiles4 records

CARA funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CARA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CARA

What does CARA do?

CARA sells AneuView™️, a cloud-native SaaS clinical decision intelligence platform that uses proprietary AI to fuse medical imaging, hemodynamic, and clinical data into interpretable brain aneurysm rupture risk predictions and neurovascular triage scores for neurospecialists at the point of care. The offering is delivered to hospitals through flexible subscription plans, pay-per-use case-based billing, and one-time implementation/onboarding fees, and includes Epic-ready EHR integration and longitudinal patient monitoring.

Is CARA a public or private company?

CARA is a private company. It is classified as venture growth investor backed and is currently operating.

When was CARA founded?

CARA was founded in 2023. It employs 1 to 10 people.

Where is CARA based?

CARA is headquartered in Brooklyn, United States, in the North America region.

How does CARA make money?

Three revenue lines are on record. Subscription Plans are the primary driver. The others are pay-per-use and one-time Implementation.

Who are CARA's main competitors?

Direct peers on record are Viz.ai, RapidAI, Aidoc, Brainomix and icometrix. Emerging players are Avicenna.AI and Nico.lab. Broad incumbents are Siemens Healthineers (AI-Rad Companion) and GE HealthCare (Edison AI). Circle Cardiovascular Imaging is listed as a regional player.

Does CARA have an API?

No public API is recorded for CARA.

What industry is CARA in?

CARA's product category is AI Clinical Decision Support for Neurovascular Care. Its primary akta.pro industry code is HLACAGAA, Diagnostic & Triage Decision Support, with a secondary code of HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML). Its NAICS code is 5132 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Next WebInside the quiet reinvention of the clinical judgment callCARA Systems Inc. developed AneuView, a non-invasive clinical decision-support platform for neurovascular assessment using AI-driven imaging and patient-specific analytics. The platform aims to reduce inter-rater variability and avoid unnecessary invasive diagnostics by providing earlier, patient-specific risk characterization. The company envisions similar integrated systems across cardiology, oncology, and acute care.International Business TimesPrithvinath Garigapuram on Healthcare’s Real AI ProblemPrithvinath Garigapuram, CEO of CARA Systems, argues clinical AI should integrate multimodal patient data into physician workflows rather than offering isolated predictions. He cites a JAMA analysis showing CT and MRI use doubled in U.S. adults, yet decision-making remains cognitively burdensome. His platform aims to provide interpretable, context-aware decision support for neurovascular care.MotortradenewsCARA launches pan-European used car grading system at VRA member meetingThe Car Remarketing Association of Europe (CARA) announced a pan-European used car grading system at the Vehicle Remarketing Association (VRA) member meeting held at Cox Automotive in Leicestershire, with the system developed over four months using decision-tree algorithms to provide consistent, automated grading across European markets. The initiative aims to establish a unified grading language for continental Europe by separating interior and exterior vehicle conditions rather than producing a single combined grade. Industry panels also discussed battery health checks for electric vehicles and market trends showing BEV values remain under pressure while petrol and diesel segments remain stable.FleetnewsUsed vehicle grading trends to be discussed at VRA meetingThe Vehicle Remarketing Association (VRA) will host its next member meeting on March 26, 2026, at Cox Automotive in Leicestershire, UK, with used vehicle grading as the central topic. Industry experts from Openlane, TradeBid, Manheim, BCA, Autorola UK, Cap HPI, and EV Essentials will deliver presentations on grading trends, vehicle markets, and the electric van sector. The meeting also marks one of the first visible outcomes of the VRA's new partnership with the Car Remarketing Association of Europe (CARA), as the organisations seek to explore standardised grading approaches across mainland Europe.